Volition Expands Contract with Fujifilm to Include the Nu.Q® Vet Test for Cats
VolitionRx (VNRX) Q3 2026 Earnings Call Transcript
VolitionRx Limited Q3 2026 Earnings Call Summary
VolitionRX: Q3 Earnings Snapshot
VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update
VolitionRX Q3 EPS $(0.21) Beats $(0.40) Estimate, Sales $1.614M Beat $706.500K Estimate
VolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business Update
VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide
VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash
VolitionRx Executes Non-Binding Letter Of Intent With Missionpharma A/S To Develop, Roll Out Volition's Prototype Lateral Flow Technology For NETosis
VolitionRx Makes $500K Cash Partial Prepayment Towards Outstanding Principal Balance On Its Senior Secured Convertible Promissory Note
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
VolitionRx Participates in Launch of DETECSEPS Program in France
VolitionRx Launches DETECSEPS Sepsis Detection Project With ~$7.3M French Government Funding
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
VolitionRx Fully Pays Off $7.5M Convertible Promissory Note, Dated May 20, 2025
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
Volitionrx Files Prospectus For Offering 10M Common Shares On Behalf Of Selling Shareholders
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.